Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ligand Pharm (LGND)

Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,799,215
  • Shares Outstanding, K 19,682
  • Annual Sales, $ 167,130 K
  • Annual Income, $ -4,030 K
  • EBIT $ 50 M
  • EBITDA $ 85 M
  • 60-Month Beta 0.99
  • Price/Sales 22.98
  • Price/Cash Flow 121.42
  • Price/Book 4.02

Options Overview Details

View History
  • Implied Volatility 30.30% (-0.01%)
  • Historical Volatility 39.01%
  • IV Percentile 4%
  • IV Rank 3.64%
  • IV High 65.30% on 04/08/25
  • IV Low 28.98% on 08/08/25
  • Expected Move (DTE 14) 4.51 (2.39%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 16
  • Volume Avg (30-Day) 33
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 747
  • Open Int (30-Day) 883
  • Expected Range 184.00 to 193.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.63
  • Number of Estimates 4
  • High Estimate 1.43
  • Low Estimate -0.52
  • Prior Year -1.64
  • Growth Rate Est. (year over year) +138.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
186.96 +0.82%
on 11/06/25
212.49 -11.29%
on 11/11/25
-0.95 (-0.50%)
since 11/04/25
3-Month
161.82 +16.49%
on 09/15/25
212.49 -11.29%
on 11/11/25
+20.76 (+12.38%)
since 09/04/25
52-Week
93.58 +101.43%
on 04/09/25
212.49 -11.29%
on 11/11/25
+67.52 (+55.81%)
since 12/04/24

Most Recent Stories

More News
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from...

LGND : 188.50 (-2.35%)
MDT : 101.99 (+0.02%)
OBIO : 4.68 (-3.70%)
Ligand: Q3 Earnings Snapshot

Ligand: Q3 Earnings Snapshot

LGND : 188.50 (-2.35%)
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

Third quarter performance driven by strong portfolio royalty revenue growth of  47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million)...

LGND : 188.50 (-2.35%)
Ligand to Participate in November Investor Conferences

JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will...

LGND : 188.50 (-2.35%)
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025....

LGND : 188.50 (-2.35%)
Ligand to Host Investor Day on December 9, 2025

JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December...

LGND : 188.50 (-2.35%)
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17 th Captisol-enabled™ approved product ...

LGND : 188.50 (-2.35%)
Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will...

LGND : 188.50 (-2.35%)
Ligand Announces Closing of Convertible Senior Notes Offering

JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”)...

LGND : 188.50 (-2.35%)
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible...

LGND : 188.50 (-2.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 200.01
2nd Resistance Point 197.45
1st Resistance Point 192.98
Last Price 188.50
1st Support Level 185.95
2nd Support Level 183.39
3rd Support Level 178.92

See More

52-Week High 212.49
Last Price 188.50
Fibonacci 61.8% 167.07
Fibonacci 50% 153.04
Fibonacci 38.2% 139.00
52-Week Low 93.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar